Our findings differ from those highlighted by Franzoi et al. in patients receiving endocrine therapy plus cyclin-dependent kinase (CDK) 4/6 inhibitors for hormone receptor-positive, HER2-negative metastastic BC: their results showed an association between sarcopenia and a worse PFS, while ours didn’t. Here, ERBB2 is linked to breast cancer.